Combinatorial Macrolide GPCR Screening Library

Information

  • Research Project
  • 6402993
  • ApplicationId
    6402993
  • Core Project Number
    R43GM064074
  • Full Project Number
    1R43GM064074-01
  • Serial Number
    64074
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2001 - 23 years ago
  • Project End Date
    1/31/2002 - 22 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    8/1/2001 - 23 years ago
  • Budget End Date
    1/31/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/28/2001 - 23 years ago
Organizations

Combinatorial Macrolide GPCR Screening Library

DESCRIPTION (provided by applicant): The long-term objective of this proposal is to identify and develop new drugs by identifying novel ligands for G protein-coupled receptors (GPCRs). GPCRs have been shown to be the molecular target of many marketed drugs. Several macrolide structures have been shown to act as agonists or antagonists against GPCRs, so a combinatorial library of macrolide structures screened against a battery of orphan GPCRs would likely yield an array of agonists and antagonists. These macrolide ligands could then be used to elucidate the biology of the orphan receptors, and would likely lead to the development and commercialization of new drugs. This proposal is thus directed towards the synthesis of a library of macrolides using high-speed parallel synthesis. During Phase I, the chemistry to produce the first two subsets of compounds will be developed, and analogs generated will be screened for activity against the motilin receptor as a proof-of-concept. Phase II will be directed to development of the remaining chemistry and the synthesis of the remaining library members. The library will be expanded to ca. 1000 members, and will be screened in collaboration with Glaxo SmithKline. PROPOSED COMMERCIAL APPLICATIONS: Agonists of the Motilin receptor could be used in the attachment of gastroesophageal reflux disease and gastroparesis. Both diseases have significant markets, and development of suitable treatments would have substantial commercial prospects. The discovery of agonist or antagonist ligands for orphan GPCRs would aid in the characterization of novel targets for new drugs.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    105000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:105000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    KOSAN BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    932981319
  • Organization City
    HAYWARD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94545
  • Organization District
    UNITED STATES